DUBLIN, May 12, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics" report to their offering.
The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021.
Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.
Viruses are infectious particles comprising a nucleic acid core - consisting of either DNA or RNA - and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question.
This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza.
Scope
The viral infections market is large and growing rapidly - How do epidemiology trends differ among the key indications? - What therapeutic options exist for preventing and treating viral infections? - Which products and companies dominate the market?
The pipeline is innovative and diverse
- What is the proportion of early- to late-stage pipeline products?
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
Considerable market growth is anticipated throughout 2021
- Which products will contribute to this growth most significantly?
- Will the current market leaders retain their dominance over the forecast period?
Deal values for licensing and co-development deals range considerably
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Marketed Products
3.1 Multiple Indications
3.1.1 Viread - Gilead
3.1.2 Epivir/Epivir-HBV - ViiV Healthcare
3.1.3 Pegasys - F. Hoffmann La Roche
3.2 Human Immunodeficiency Virus (HIV)
3.2.1 Truvada - Gilead
3.2.2 Atripla - Gilead
3.2.3 Stribild - Gilead
3.2.4 Tivicay - ViiV Healthcare
3.2.5 Triumeq - ViiV Healthcare
3.2.6 Genvoya - Gilead
3.3 Hepatitis C Virus (HCV)
3.3.1 Olysio - Janssen
3.3.2 Sovaldi and Harvoni - Gilead
3.3.3 Zepatier - Merck and Co.
3.4 Hepatitis B Virus
3.4.1 Baraclude - Bristol-Myers Squibb
3.5 Influenza Virus
3.5.1 Tamiflu - Roche
4 Pipeline
4.1 Overview
4.2 Pipeline Products by Stage of Development and Molecule Type
4.3 Pipeline Products by Molecular Target
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Sofosbuvir in Combination with Velpatasvir - Gilead
4.5.2 Tenofovir alafenamide fumarate - Gilead
4.5.3 Descovy - Gilead
4.5.4 Cobicistat, darunavir, emtricitabine and TAF - Johnson & Johnson
4.5.5 Beclabuvir hydrochloride - Bristol-Myers Squibb
4.5.6 V-212 - Merck
5 Multi-scenario Market Forecast to 2021
5.1 Revenues Analysis by Molecular Target
5.1.1 Reverse Transcriptase
5.1.2 Nonstructural Protein 5B Polymerase and Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A
5.1.3 HIV Integrase
5.1.4 Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase
5.1.5 NS3-4A Protease/Nonstructural Protein 5A
5.2 Revenue and Market Share Analysis by Company
5.2.1 Gilead Sciences - Monopolization of Market to Continue Throughout 2021
5.2.2 Merck - Uptake of Zepatier and Gardasil 9 to Encourage Strong Growth
5.2.3 GlaxoSmithKline - Tivicay and Triumeq to Propel Company Revenues
5.2.4 Johnson and Johnson - Market Share to Dwindle as Sales for Prezista and Olysio Decline
5.2.5 Bristol-Myers Squibb - Marginalization Due to Patent Expirations
6 Company Analysis and Positioning
7 Strategic Consolidations
7.1 Licensing Deals
7.2 Co-development Deals
8 Appendix
For more information visit http://www.researchandmarkets.com/research/ktb37l/global_viral
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
